Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
Aspirin (acetylsalicylic acid; ASA) (1) ·
Celecoxib (1) ·
Diclofenac (sodium, potassium, epolamine; multiple salt forms) (1) ·
Ibuprofen (1) ·
Indomethacin (1) ·
Meloxicam (1) ·
Morphine (sulfate) (1) ·
Naproxen (sodium; free acid) (1) ·
Oxycodone (hydrochloride) (1) ·
Rizatriptan (benzoate) (1) ·
Sumatriptan (succinate) (1) ·
Tramadol (1)
brand:
Advil, Motrin, IBU, Caldolor (IV), NeoProfen (neonatal IV) (1) ·
Aleve (OTC), Naprosyn (Rx), Anaprox (Rx), Naprelan (ER), EC-Naprosyn (enteric-coated), Vimovo (with esomeprazole) (1) ·
Bayer, Ecotrin, Bufferin, St. Joseph (low-dose 81 mg), Excedrin (with acetaminophen and caffeine) (1) ·
Celebrex (oral capsules), Elyxyb (oral solution, for acute migraine) (1) ·
Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) (1) ·
Indocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon (1) ·
Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet) (1) ·
Mobic, Vivlodex (lower-dose capsules), Anjeso (IV) (1) ·
MS Contin (ER), Kadian (ER), Avinza (ER), Roxanol (IR oral solution), Duramorph (epidural / IT), Astramorph (IV), Infumorph (intrathecal pump), MorphaBond (IR abuse-deterrent) (1) ·
OxyContin (ER), Roxicodone (IR), Oxaydo (IR abuse-deterrent), Xtampza ER (abuse-deterrent ER) (1) ·
Ultram (IR), Ultram ER, ConZip ER (1) ·
Voltaren (IR oral, topical gel), Cataflam (potassium IR), Cambia (oral powder, migraine), Zorvolex (low-dose), Pennsaid (topical 2% solution), Flector (transdermal patch), Solaraze (3% gel for actinic keratosis) (1)
classes: (Click arrow to add another value)
mechanism:
uses:
'"`UNIQ--vote-00000011-QINU`"' (1) ·
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (2) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (2) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (2) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"' (1) ·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (3)
starting dose:
200-400 mg PO every 4-6 hours as needed. OTC max 1200 mg/day without provider direction; prescription max 3200 mg/day divided (1) ·
5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours (1) ·
7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg (1) ·
Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) ·
Antiplatelet: 81 mg PO once daily. Acute MI/stroke: 162-325 mg chewed. Analgesic: 325-650 mg PO every 4-6 hours as needed (1) ·
IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: '''10 mg PO every 12 hours (lowest available)'''; titrate slowly to clinical effect (1) ·
IR oral 50 mg PO TID or 75 mg BID. Voltaren 1% gel: apply 2-4 g to affected area QID. Pennsaid 2%: 40 drops to knee BID. Flector patch: every 12 hours (1) ·
IR oral: 15-30 mg every 4 hours as needed. ER opioid-naive: 15-30 mg every 12 hours. IV/IM/SC: 2-10 mg every 3-4 hours. Epidural / intrathecal: see surgical or palliative-care protocols (1) ·
IR: 25-50 mg PO every 4-6 hours as needed, titrate as tolerated. ER: 100 mg PO once daily, titrate by 100 mg every 5 days (1) ·
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours (1) ·
Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours (1) ·
OTC: 220 mg PO every 8-12 hours, max 660 mg/24h. Rx: 250-500 mg PO BID. Acute gout: 750 mg loading then 250 mg every 8 hours (1)
preparations:
Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) ·
Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL (1) ·
IR tablets 15, 30 mg; oral solution 10 mg/5 mL, 20 mg/mL, 100 mg/5 mL (concentrated); suppositories; ER tablets and capsules in multiple strengths; injectable 0.5-50 mg/mL (1) ·
IR tablets 25, 50 mg; ER tablets 100 mg; Cataflam IR 50 mg; Zorvolex 18, 35 mg; Voltaren gel 1%; Pennsaid 2% topical solution; Flector transdermal patch; Solaraze 3% gel; Cambia oral powder 50 mg (1) ·
IR tablets 5, 7.5, 10, 15, 20, 30 mg; IR oral solution 5 mg/5 mL; concentrated solution 20 mg/mL; OxyContin ER tablets 10, 15, 20, 30, 40, 60, 80 mg; Xtampza ER capsules (1) ·
IR tablets 50 mg; ER tablets 100, 200, 300 mg (Ultram ER, ConZip); oral solution 5 mg/mL; combination products with acetaminophen (Ultracet) (1) ·
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1) ·
OTC tablets 220 mg; Rx tablets 250, 375, 500 mg; ER tablets 375, 500, 750 mg (Naprelan); oral suspension 125 mg/5 mL; enteric-coated tablets (EC-Naprosyn) (1) ·
Tablets 200, 400, 600, 800 mg; capsules 200 mg; oral suspension 100 mg/5 mL; chewable tablets 100 mg; injection 100 mg/mL (Caldolor) (1) ·
Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg (1) ·
Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso) (1) ·
Tablets 81 (low-dose), 325, 500, 650 mg; chewable 81 mg; enteric-coated tablets; effervescent tablets; suppositories (1)
fda max:
15 mg/day (oral); 30 mg IV once daily (Anjeso) (1) ·
150 mg/day (oral); use lowest effective dose for shortest duration per FDA NSAID class guidance (1) ·
1500 mg/day (Rx); 660 mg/24h (OTC, without provider direction) (1) ·
200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra) (1) ·
200 mg/day (typical adult oral) (1) ·
30 mg/24 hours (1) ·
3200 mg/day (Rx); 1200 mg/day (OTC, without provider direction) (1) ·
400 mg/day (IR, adult); 300 mg/day (ER); 300 mg/day in elderly >75 years (1) ·
400 mg/day for chronic indications; higher for short-term acute pain (1) ·
4000 mg/day (analgesic) (1) ·
No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals (2)
routes: (Click arrow to add another value)
onset:
10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) (1) ·
10-30 minutes (IR) (1) ·
30 minutes for migraine relief (1) ·
30-60 minutes (2) ·
30-60 minutes (IR) (1) ·
30-60 minutes (oral) (1) ·
30-60 minutes (oral); rapid relief in acute gout (1) ·
30-60 minutes (oral); slower for topical (1) ·
5-10 minutes (IV); 30 minutes (oral IR); slower for ER and rectal (1) ·
Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks (1) ·
Antiplatelet effect within 30-60 minutes; analgesic effect 30-60 minutes (1)
duration:
'''Antiplatelet effect lasts the platelet's lifetime (~7-10 days)''' due to irreversible COX-1 acetylation; analgesic 4-6 hours (1) ·
12-24 hours (1) ·
2-4 hours; headache recurrence rate ~20-30% within 24 hours (1) ·
24 hours (once-daily dosing supported by long half-life) (1) ·
3-5 hours (IR); 8-24 hours (ER); 12-24 hours (epidural / intrathecal) (1) ·
4-6 hours (1) ·
4-6 hours (IR); 12 hours (ER) (1) ·
4-6 hours (IR); 24 hours (ER) (2) ·
4-6 hours; headache recurrence is common (1) ·
6-8 hours (IR oral); 12-24 hours (ER) (1) ·
8-12 hours (the long-duration feature relative to ibuprofen) (1)
halflife:
1-2 hours (parent compound)'"`UNIQ--ref-00000029-QINU`"' (1) ·
12-17 hours'"`UNIQ--ref-00000029-QINU`"' (1) ·
15-20 hours'"`UNIQ--ref-00000020-QINU`"' (1) ·
2 hours'"`UNIQ--ref-00000015-QINU`"' (1) ·
2-3 hours'"`UNIQ--ref-00000012-QINU`"' (1) ·
2-4 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
3-5 hours (IR); 4.5 hours (ER)'"`UNIQ--ref-0000001D-QINU`"' (1) ·
4-5 hours'"`UNIQ--ref-00000026-QINU`"' (1) ·
Aspirin 15-30 minutes; salicylate metabolite 2-3 hours (concentration-dependent, saturable at high doses)'"`UNIQ--ref-00000027-QINU`"' (1) ·
Morphine 2-4 hours; morphine-6-glucuronide active metabolite 2-4 hours (longer with renal impairment)'"`UNIQ--ref-00000020-QINU`"' (1) ·
Tramadol 6-7 hours; M1 active metabolite 7-9 hours'"`UNIQ--ref-0000001D-QINU`"' (1) ·
~11 hours'"`UNIQ--ref-00000029-QINU`"' (1)
bioavailability:
~100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' (1) ·
~25-40% (oral; extensive first-pass)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"' (1) ·
~50% (oral; reduced by buffering and enteric coating but onset clinically similar)'"`UNIQ--ref-00000028-QINU`"' (1) ·
~50-60% (oral; substantial first-pass metabolism)'"`UNIQ--ref-0000002A-QINU`"' (1) ·
~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)'"`UNIQ--ref-0000001E-QINU`"' (1) ·
~75% (IR, rises with multi-dose administration due to saturable first-pass)'"`UNIQ--ref-0000001E-QINU`"' (1) ·
~80-100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) ·
~89% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~95% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1) ·
~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1)
pregnancy:
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000022-QINU`"' (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000028-QINU`"' (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (3) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) ·
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3) ·
Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Low-dose (81 mg) safe and indicated for preeclampsia prophylaxis after 12 weeks in high-risk patients per USPSTF; high-dose aspirin avoid third trimester due to premature ductus arteriosus closure and bleeding risk (1)
legal:
[[USLegal:Over-the-counter|OTC]] in the US at ≤200 mg per tablet / ≤1200 mg/day; [[USLegal:Prescription only|Rx-only]] at higher strengths and indications (1) ·
[[USLegal:Over-the-counter|OTC]] in US at all standard strengths (1) ·
[[USLegal:Over-the-counter|OTC]] in US at ≤220 mg/tablet and ≤660 mg/day; [[USLegal:Prescription only|Rx-only]] at higher strengths (1) ·
[[USLegal:Prescription only|Rx-only]] for oral and most topical formulations in US; Voltaren Arthritis Pain 1% gel switched to [[USLegal:Over-the-counter|OTC]] in 2020 (1) ·
[[USLegal:Prescription only|Rx-only]] in US (5) ·
[[USLegal:Schedule II|Schedule II controlled substance]] in US; WHO essential medicine'"`UNIQ--ref-00000022-QINU`"' (1) ·
[[USLegal:Schedule II|Schedule II controlled substance]] in US'"`UNIQ--ref-0000001F-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (federally scheduled 2014); some states schedule higher'"`UNIQ--ref-0000001F-QINU`"' (1)
Showing below up to 12 results in range #1 to #12.